Preclinical models provided ample evidence that cannabinoids are cytotoxic against cancer cells. Among the best studied phytocannabinoids, cannabidiol (CBD) is most promising for the treatment of cancer as it lacks the psychotomimetic properties of delta-9-tetrahydrocannabinol (THC).
Cannabidiol (CBD) has demonstrated anti-inflammatory, analgesic, anxiolytic and neuroprotective effects that have the potential to benefit athletes. This pilot study investigated the effects of acute, oral CBD treatment on physiological and psychological responses to aerobic exercise to determine its practical utility within the sporting context.
Combination tetrahydrocannabinol (THC)/cannabidiol (CBD) medicines or CBD-only medicines are prospective treatments for chronic pain, stress, anxiety, depression, and insomnia. THC and CBD increase signaling from cannabinoid receptors, which reduces synaptic transmission in parts of the central and peripheral nervous systems and reduces the secretion of inflammatory factors from immune and glial cells.
After a traumatic childhood in Europe during the Second World War, I found that scientific research in Israel was a pleasure beyond my expectations. Over the last 65 year, I have worked on the chemistry and pharmacology of natural products
Authors Andrea M. Tomko, Erin G. Whynot & Denis J. Dupré Published 22 July, 2022 DOI: 10.1186/s42238-022-00151-y Citations Tomko, A.M., Whynot, E.G. & Dupré, D.J. Anti-cancer properties of cannflavin A…
Authors Zhanna Yekhtin, Iman Khuja, David Meiri, Reuven Or, Osnat Almogi-Hazan Published 26 July 2022 DOI: 10.3390/biomedicines10081793 Citations MDPI and ACS Style Yekhtin, Z.; Khuja, I.; Meiri, D.; Or, R.;…
Some patients diagnosed with cancer use medical cannabis to self-manage undesirable symptoms, including nausea and pain. To improve patient safety and oncological care quality, the routes of administration for use of medical cannabis, patients’ reasons, and prescribed indications must be better understood.
Posttraumatic stress disorder (PTSD) may stem from the formation of aberrant and enduring aversive memories. Some PTSD patients have recreationally used Cannabis, probably aiming at relieving their symptomatology. However, it is still largely unknown whether and how Cannabis or its psychotomimetic compound Δ9-tetrahydrocannabinol (THC) attenuates the aversive/traumatic memory outcomes. Here, we seek to review and discuss the effects of THC on aversive memory extinction and anxiety in healthy humans and PTSD patients.
Cannabidiol (CBD) is one of the main constituents of the plant Cannabis sativa.
Surveys suggest that medicinal cannabis is popular amongst people diagnosed with cancer. CBD
is one of the key constituents of cannabis, and does not have the potentially intoxicating effects
that tetrahydrocannabinol (THC), the other key phytocannabinoid has. Research indicates the CBD
may have potential for the treatment of cancer, including the symptoms and signs associated with
cancer and its treatment. Preclinical research suggests CBD may address many of the pathways
involved in the pathogenesis of cancers. Preclinical and clinical research also suggests some evidence
of efficacy, alone or in some cases in conjunction with tetrahydrocannabinol (THC, the other key
phytocannabinoid in cannabis), in treating cancer-associated pain, anxiety and depression, sleep
problems, nausea and vomiting, and oral mucositis that are associated with cancer and/or its
treatment. Studies also suggest that CBD may enhance orthodox treatments with chemotherapeutic
agents and radiation therapy and protect against neural and organ damage. CBD shows promise as
part of an integrative approach to the management of cancer.
We previously reported that both cannabidiol (CBD) and low‑dose naltrexone (LDN) exhibit complex effects on G‑protein coupled receptors, which can impact the expression and function of other members of this superfamily. These receptors feed into and interact with central signalling cascades that determine the ease by which cells engage in apoptosis, and can be used as a way to prime cancer cells to other treatments. The present study was designed to investigate the effect of combining these two agents on cancer cell lines in vitro and in a mouse model, and focused on how the sequence of administration may affect the overall action. The results showed both agents had minimal effect on cell numbers when used simultaneously; however, the combination of LDN and CBD, delivered in this specific sequence, significantly reduced the number of cells, and was superior to the regimen where the order of the agents was reversed. For example, there was a 35% reduction in cell numbers when using LDN before CBD compared to a 22% reduction when using CBD before LDN. The two agents also sensitised cells to chemotherapy as significant decreases in cell viability were observed when they were used before chemotherapy. In mouse models, the use of both agents enhanced the effect of gemcitabine, and crucially, their use resulted in no significant toxicity in the mice, which actually gained more weight compared to those without this pre‑treatment (+6.5 vs. 0%). Overall, the results highlight the importance of drug sequence when using these drugs. There is also a need to translate these observations into standard chemotherapy regimens, especially for common tumour types where treatment is often not completed due to toxicities.
In recent years, cannabinoid products have gained popularity among the general public. The anti-inflammatory properties of cannabinoids have piqued the interest of researchers and clinicians, as they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refractory to conventional therapy. The objective of this study was to review the existing literature regarding cannabinoids for dermatologic conditions.
We report our findings regarding effectiveness, safety, and tolerability of cannabidiol (CBD)-enriched medical cannabis as add-on therapy in children with drug-resistant epileptic encephalopathies (DEEs) after a median follow-up of 20 months.